Namrata Goel, MD
Nephrology · Houston, TXNPI 1497862247
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $301,263 of the $425,953 with a category attached, or 70.7%. Amgen accounts for 98.5% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2023 at $143,630 and has fallen 65.0% since, to $50,260 in 2025. Among nephrology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 775 payments — averaging $549.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$420K
- Sobi, Inc$2K
- Vifor Pharma, Inc.$1K
- AstraZeneca$807
- Bayer$332
- ANI Pharmaceuticals, Inc.$245
- plus $2K from 17 others
What the payments were for
- Consulting fees$13,3603%
- Speaking & faculty fees$301,26371%
- Travel & lodging$97,17123%
- Food & beverage$14,0763%
- Education$830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 591 | $419,503 |
| Sobi, Inc | 4 | $2,380 |
| Vifor Pharma, Inc. | 35 | $1,042 |
| AstraZeneca(2 entities) | 39 | $807 |
| Bayer | 17 | $332 |
| ANI Pharmaceuticals, Inc. | 8 | $245 |
| Novartis | 8 | $227 |
| Ardelyx, Inc. | 10 | $213 |
| Calliditas Therapeutics US Inc. | 10 | $196 |
| Otsuka America Pharmaceutical, Inc. | 8 | $187 |
| Travere Therapeutics, Inc. | 9 | $166 |
| Fresenius USA Marketing, Inc. | 8 | $140 |
| Philips North America LLC | 6 | $98 |
| Mallinckrodt Enterprises LLC | 5 | $78 |
| Akebia Therapeutics Inc | 3 | $66 |
| GSK | 3 | $56 |
| Aurinia Pharma U.S., Inc. | 2 | $47 |
| Mallinckrodt Hospital Products Inc. | 2 | $42 |
| Daiichi Sankyo Inc. | 2 | $37 |
| OPKO Pharmaceuticals, LLC | 2 | $35 |
| Abbott | 1 | $23 |
| Lilly USA, LLC | 1 | $20 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$413,258
- Gamifant$2,266
- Veltassa$334
- PURIFIED CORTROPHIN GEL$101
How this compares
$425,953 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 16 | $57,108 |
| VeltassaPatiromer Calcium Sorbitex | 36 | $44,496 |
| RenvelaSevelamer Carbonate | 14 | $39,700 |
| Sevelamer Carbonate | 124 | $24,937 |
| OzempicSemaglutide | 21 | $18,339 |
| LokelmaSodium Zirconium Cyclosilicate | 20 | $16,104 |
| JardianceEmpagliflozin | 20 | $12,148 |
| Mycophenolate Mofetil | 12 | $3,460 |
| Nifedipine ErNifedipine | 96 | $2,616 |
| Febuxostat | 13 | $2,421 |
| Bumetanide | 19 | $1,541 |
| ProsolParenteral Amino Acid 20% No.1 | 12 | $1,266 |
| Olmesartan Medoxomil | 14 | $1,090 |
| Labetalol Hcl | 18 | $831 |
| Allopurinol | 77 | $737 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $140 | $57,10816 claims |
| Novo NordiskOzempic | $14 | $18,33921 claims |
| AstraZenecaLokelma | $807 | $16,10420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,070 nephrology providers in Texas.
Other nephrology in Houston
- Sreedhar MandayamHouston$752K
- Christopher KwohHouston$467K
- Wolfgang WinkelmayerHouston$462K
- Dana MitchellHouston$344K
- Ramachandra MalyaHouston$312K
- John ForingerHouston$215K
- Biruh WorkenehHouston$185K
- Horacio AdrogueHouston$122K
- Anand SaranathanHouston$109K
- Kevin EricksonHouston$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.